The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets - Uchida, S; Soshiroda, K; Okita, E (Eur J Pharmacol, 2015)
et al.